Immunocore Holdings (IMCR) Accumulated Expenses (2019 - 2026)

Immunocore Holdings has disclosed Accumulated Expenses across 8 years of filings, most recently posting $207.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $207.4 million, up 75.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $207.4 million (up 75.25% YoY), and the FY2025 annual result was $219.7 million, up 18.44% from the prior year.
• Accumulated Expenses came in at $207.4 million for Q1 2026 at Immunocore Holdings, down from $219.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $219.7 million in Q4 2025 to a low of $5.5 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $144.9 million (2025), against an average of $143.6 million.
• Peak annual rise in Accumulated Expenses reached 2039.6% in 2025, while the deepest fall reached 26.51% in 2025.
• Immunocore Holdings' Accumulated Expenses stood at $73.2 million in 2022, then jumped by 63.73% to $119.8 million in 2023, then surged by 54.82% to $185.5 million in 2024, then grew by 18.44% to $219.7 million in 2025, then decreased by 5.62% to $207.4 million in 2026.
• The last three Accumulated Expenses figures came in at $207.4 million (Q1 2026), $219.7 million (Q4 2025), and $144.9 million (Q3 2025), per Business Quant data.